Skip to content

Effect of Delmopinol on treatment of Peri - implant mucositis : a randomised controlled clinical trial

Effect of Delmopinol on treatment of Peri - implant mucositis : a randomised controlled clinical trial - Effect of Delmopinol on treatment of Peri - implant mucositis

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON43871
Enrollment
75
Registered
2016-11-16
Start date
2017-04-18
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

periimplant mucositis Inflammation around dental implants

Interventions

First group receives mechanical debridement together with a placebo mouth rinse solution. The second group receives mechanical debridement together Delmopinol Mouth rinse solution (consisting of 0.2
Delmopinol
Effect
periimplantmucositis

Sponsors

Vrije Universiteit
Lead Sponsor

Eligibility

Age
18 Years to 64 Years

Inclusion criteria

Inclusion criteria: * Bleeding on probing and/ pus around at least one dental implant * Implant in function for at least 1 year, no radiographic bone loss more than 1.8mm compared to the baseline radiograph. * Signed Informed consent

Exclusion criteria

Exclusion criteria: * Perimplantitis with more than 1,8mm bone loss as identified by comparisons between current radiographs with radiographs taken at baseline. * Smoking >20 sig/day * Patients with uncontrolled Diabetes mellitus * Untreated periodontitis * Antibiotic and anti-inflammatory drug use ongoing / in the last one month before the start of the study * Pregnancy / lactation

Design outcomes

Primary

MeasureTime frame
The main outcome is difference in bleeding on probing on four sites around the dental implant (buccal, lingual, mesial and distal).

Secondary

MeasureTime frame
Secondary parameters include Pocket probing depth, Plaque and microbiological changes.

Countries

The Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)